Table 3 Cox proportional hazards regression models examining the prognostic value of clinical factors and signatures derived from single proteins and apoptosis modelling
From: System-based approaches as prognostic tools for glioblastoma
| Predictors | HR | 95% CI | P |
|---|---|---|---|
| Age (continuous, n = 46) | 1.02 | 1.00–1.05 | 0.06 |
| Sex (ref. M, n = 24) | 0.40 | ||
| F (n = 22) | 0.76 | 0.41–1.43 | |
| Location (ref. left side, n = 13) | 0.58 | ||
| Right side (n = 28) | 1.28 | 0.62–2.64 | |
| Other (n = 4) | 0.73 | 0.20–2.66 | |
| History (ref. newly-diagnosed - no treatment, n = 31) | 0.06 | ||
| Recurrent - no treatment (n = 6) | 1.86 | 0.69–5.01 | |
| Recurrent - treatment (n = 9) | 2.73 | 1.19–6.25 | |
| MGMT promoter methylation (ref. methylated, n = 17) | 0.52 | ||
| Unmethylated (n = 22) | 1.26 | 0.62–2.59 | |
| Apaf-1 (ref. >median, n = 23) | 0.20 | ||
| ≤ median (n = 23) | 1.52 | 0.80–2.87 | |
| Procaspase-3 (ref. >median, n = 23) | 0.06 | ||
| ≤ median (n = 23) | 1.91 | 0.99–3.69 | |
| Procaspase-9 (ref. >median, n = 23) | 0.49 | ||
| ≤ median (n = 23) | 1.25 | 0.66–2.37 | |
| SMAC (ref. >median, n = 23) | 0.38 | ||
| ≤ median (n = 23) | 1.34 | 0.70–2.55 | |
| XIAP (ref. >median, n = 23) | 0.47 | ||
| ≤ median (n = 23) | 1.27 | 0.67–2.40 | |
| Apoptosis susceptibility (ref. SC > 80%, n = 37) | 0.001 | ||
| SC ≤ 80% (n = 9) | 5.02 | 2.04–12.33 | |
| Adjusted apoptosis susceptibility (ref. SC > 80%, n = 37)a | 0.006 | ||
| SC ≤ 80% (n = 9) | 4.40 | 1.59–12.14 |
